Leptin down-regulates peroxisome proliferator-activated receptor γ (PPARγ) mRNA levels in primary human monocyte-derived macrophages

Molecular and Cellular Biochemistry

Volumn 275, Issue 1-2, 2005, Pages 173-179

  Cabrero, Àgatha ^a   Cubero, Marta ^a   Llaverías, Gemma ^a   Alegret, Marta ^a   Sánchez, Rosa ^a   Laguna, Juan Carlos ^a   Vázquez Carrera, Manuel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ABCA1; CPT I; Foam cell; Leptin; Macrophage; PPAR

Indexed keywords

ABC TRANSPORTER A1; CARNITINE PALMITOYLTRANSFERASE; CD36 ANTIGEN; CHOLESTEROL ESTER; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECOMBINANT LEPTIN;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; FOAM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MACROPHAGE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK FACTOR;

ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; DOWN-REGULATION; GENE EXPRESSION REGULATION; HUMANS; LEPTIN; MACROPHAGES; MONOCYTES; PPAR GAMMA; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 22744444091     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11010-005-1353-8     Document Type: Article

References (25)

1. Guyton J.R. The arterial wall and the atherosclerotic lesion. Curr Opin Lipidol 5: 376-381, 1994
2. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 20: 649-688, 1999
3. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM: PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252, 1998
4. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B: PPARα and PPARγactivators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Med 7: 53-58, 2001
5. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347, 849-853, 1996
6. Rosen ED, Spiegelman BM: Peroxisome ProliferatorActivated Receptor-γ ligands and atherosclerosis: Ending the heartache. J Clin Invest 106: 629-631, 2000
7. McGill HC, McMahan CA, Malcom GT, Oalmann MC, Strong JP: PDAY Research Group. Relation to glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol 15: 431-438, 1995
8. Jensen NS: Obesity and cardiovascular disease: Is body structure a factor? Curr Opin Lipidol 8: 200-204, 1997
9. Young JL, Libby P, Schonbeck U: Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 88: 554-567, 2002
10. Haverkate F: Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vascul Pharmacol 39: 109-112, 2002
11. Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV: Leptin: The tale of an obesity gene. Diabetes 45: 1455-1462, 1996
12. Lollmann B, Gruninger S, Stricker-Kongrad A, Chiesi M: Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues. Biochem Biophys Res Commun 238: 648-652, 1997
13. Lee FY, Li Y, Yang EK, Yang SQ, Lin HZ, Trush MA, Dannenberg AJ, Diehl AM: Phenotypic abnormalities in macrophages from leptin-deficient, obese mice. Am J Physiol 276: C386-C395, 1999
14. Söderberg S, Ahrén B, Jansson J-H, Johnson O, Hallmans G, Asplund K, Olsson T: Leptin is associated with increased risk of myocardial infarction. J Intern Med 246: 409-418, 1999
15. Leyva F, Godsland IF, Ghatei M, Proudler AJ, Aldis S, Walton C, Bloom S, Stevenson JC: Hyperleptinemia as a component of a metabolic syndrome of cardiovascular disease. Arterioscler Thromb Vasc Biol 18: 928-933, 1998
16. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N: Plasma leptin and the risk of cardiovascular disease in the west of Scotland Coronary Prevention Study (WOSCOPS). Circulation 104: 3052-3056, 2001
17. Vázquez M, Zambón D, Hernández Y, Adzet T, Merlos M, Ros E, Laguna JC: Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia. Br J Clin Pharmacol 45: 265-269, 1998
18. Basu SK, Goldstein JL, Anderson RG, Brown MS: Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci USA 73: 3178-3182, 1976
19. Freeman WM, Walker SJ, Kent EV: Quantitative RT-PCR: Pitfalls and Potential. Biotechniques 26: 112-125, 1999
20. Klansek JJ, Yancey P, St Clair RW, Fischer RT, Johnson WJ, Glick JM: Cholesterol quantitation by GLC: Artifactual formation of short-chain steryl esters. J Lipid Res 36: 2261-2266, 1995
21. Guardiola F, Codony R, Rafecas M, Boatella J: Selective gas chromatographic determination of cholesterol in eggs. J Am Oil Chem Soc 71: 867-871, 1994
22. Zhou Y-T, Whang Z-W, Higa M, Newgard CB, Unger RH: Reversing adipocyte differentiation: Implications for treatment of obesity. Proc Natl Acad Sci USA 96: 2391-2395, 1999
23. Pelton PD, Zhou L, Demarest KT, Burris TP: PPARγ activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem Biophys Res Commun 261: 456-458, 1999
24. Wang X, Reape TJ, Li X, Rayner K, Webb CL, Burnand KG, Lysko PG: Induced expression of adipophilin mRNA in human macrophages stimulated with oxidized low-density lipoprotein and in atherosclerotic lesions. FEBS Lett 462: 145-150, 1999
25. Barter PJ, Rye KA: High density lipoproteins and coronary heart disease. Atherosclerosis 121: 1-5, 1996